HUA MEDICINE (SHANGHAI) LTD. Funds and ETFs Hua Medicine (Shanghai) Ltd.
Equities
2552
KYG4644K1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.53 HKD | +0.66% |
|
-4.38% | -22.34% |
| 03-28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
ETFs positioned on Hua Medicine (Shanghai) Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.66% | 4 M€ | -27.92% | ||
| 0.00% | 112 M€ | +5.58% | - | |
| 0.00% | 4 M€ | -4.41% | - |
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Calendar
26/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.53
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| -22.34% | 192M | |
| +7.60% | 111B | |
| +11.36% | 106B | |
| -12.40% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.95% | 16.81B | |
| +38.07% | 12.54B | |
| -24.36% | 8.09B |
- Stock Market
- Equities
- 2552 Stock
- Funds and ETFs Hua Medicine (Shanghai) Ltd.
